Sagimet Biosciences Files 8-K Report

Ticker: SGMT · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1400118

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

Sagimet Biosciences filed an 8-K, mostly financial docs. No major news.

AI Summary

On July 2, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events detailed in the provided excerpt. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and headquartered in San Mateo, California.

Why It Matters

This 8-K filing indicates a routine update or submission of financial information and exhibits by Sagimet Biosciences Inc. to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Sagimet Biosciences Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.

When was the report filed with the SEC?

The report was filed on July 2, 2024.

What was Sagimet Biosciences Inc. formerly known as?

Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc.

Where are Sagimet Biosciences Inc.'s principal executive offices located?

Sagimet Biosciences Inc.'s principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.

Does this filing indicate any specific 'Other Events' for Sagimet Biosciences Inc.?

The filing lists 'Other Events' as an item information category, but the provided excerpt does not detail any specific events under this category.

Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-07-02 17:26:42

Key Financial Figures

Filing Documents

01

Item 8.01 Other Events. On July 2, 2024, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated July 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: July 2, 2024 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing